Kissei reports a buyback update for Kissei stock

Published on 10/20/2026 at 00:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kissei's May 11, 2026 plan covered 1,300,000 shares. For Kissei stock, Tavneos guidance fell from JPY 12.70 billion to JPY 5.10 billion.

Buyback and forecast pressure

Kissei dated its buyback update October 5, 2026.
Tavneos sales guidance fell from JPY 12.70 billion to JPY 5.10 billion.
Kissei stock closed at JPY 3,785.00 on October 19, 2026 in Tokyo.
Next earnings are scheduled for November 4, 2026.

Kissei, JP3240600001, Illustration mit AI erstellt.

Kissei (ISIN JP3240600001) closed at JPY 3,785.00 on the Tokyo Stock Exchange on October 19, 2026. Minkabu reported a company buyback update dated October 5, 2026.

Buyback plan remains a reference

The broader repurchase program was announced on May 11, 2026 and covered up to 1,300,000 shares, equal to 3.14 percent of the share capital, for JPY 6,000 million, according to JPX Market Explorer. The authorization runs through December 31, 2026, giving the company a defined framework for capital returns.

What does Tavneos mean for earnings?

The central operating pressure is Tavneos. Kissei's full-year sales forecast for the drug fell from JPY 12.70 billion to JPY 5.10 billion in the July 2026 revision, while the group operating-profit forecast was cut by about 55 percent, according to Biosector. The same analysis said first-quarter Tavneos sales fell 23.1 percent year over year.

Kissei also reported JPY 23.39 billion of revenue and JPY 4.72 billion of net income for the quarter reported on July 31, 2026. TradingView listed the net-income comparison at JPY 2.76 billion for the preceding quarter, while its revenue estimate was JPY 22.53 billion against the reported JPY 23.39 billion, a JPY 0.86 billion difference.

Next reporting date is November 4

TradingView lists November 4, 2026 as Kissei's next earnings date. That date gives investors the next scheduled checkpoint for the revised Tavneos outlook and the company's broader fiscal 2027 results.

Stock valuation and trading context

Kissei had a market capitalization of JPY 156.9 billion on October 19, 2026, based on the finance snapshot. The same market context placed its 52-week range at JPY 3,500.00 to JPY 5,040.00, leaving the October 19 close JPY 285.00 above the low and JPY 1,255.00 below the high.

Kissei operates in pharmaceuticals and is listed on the Tokyo Stock Exchange under ticker 4547. Its reported fiscal-year revenue was JPY 97.41 billion and net income was JPY 13.78 billion, figures shown in the company profile for the fiscal year ending March 2027 by MarketWatch.